The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28233679 |
2 |
Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain. |
South Dakota State University |
| 27517811 |
12 |
Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment. |
Korea Institutes of Science and Technology (KIST) |
| 27933950 |
304 |
Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers. |
Actelion Pharmaceuticals Ltd |
| 27579577 |
91 |
Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers. |
Actelion Pharmaceuticals Ltd |
| 26231163 |
50 |
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers. |
Actelion Pharmaceuticals Ltd |
| 26101566 |
14 |
Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639. |
AbbVie Inc |
| 25155913 |
32 |
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. |
AstraZeneca |
| 23200256 |
54 |
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor. |
AstraZeneca |
| 18160281 |
10 |
Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core. |
Bristol-Myers Squibb R & D |
| 21316226 |
12 |
Pyridyl amides as potent inhibitors of T-type calcium channels. |
Merck Research Laboratories |
| 20934333 |
2 |
Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists. |
Icagen Inc |
| 20659804 |
19 |
Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity. |
Ewha Womans University |
| 20580233 |
82 |
T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis. |
Merck Research Laboratory |
| 30031654 |
14 |
Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers. |
University of Toyama |
| 29622412 |
64 |
Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels. |
IITB-Monash Research Academy |
| 30034586 |
90 |
Design of Selective sPLA |
AstraZeneca |
| 29116786 |
265 |
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies. |
Idorsia Pharmaceuticals Ltd. |
| 29074257 |
115 |
Discovery and evaluation of Ca |
Idorsia Pharmaceuticals Ltd. |
| 29066309 |
87 |
Discovery and evaluation of Ca |
Idorsia Pharmaceuticals Ltd. |
| 28720324 |
7 |
Synthesis and diabetic neuropathic pain-alleviating effects of 2N-(pyrazol-3-yl)methylbenzo[d]isothiazole-1,1-dioxide derivatives. |
Korea University of Science and Technology (UST) |
| 28720332 |
3 |
Synthesis and biological evaluation of fluoro-substituted 3,4-dihydroquinazoline derivatives for cytotoxic and analgesic effects. |
Kyung Hee University |
| 28530802 |
121 |
Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. |
Vanderbilt University Institute of Imaging Science |
| 12534275 |
32 |
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. |
The Johns Hopkins University |
Search and Browse
